miércoles, 17 de mayo de 2017

Journal for ImmunoTherapy of Cancer | Case Reports

Journal for ImmunoTherapy of Cancer | Case Reports

Biomed Central

Journal for ImmunoTherapy of Cancer

JITC logo

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)

Case Reports

Section edited by Alfred Zippelius, MD
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.


    Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

    Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence ...
    James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra and Colleen Veloski
    Journal for ImmunoTherapy of Cancer 2017 5:40
    Published on: 16 May 2017

    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

    Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic cas...
    Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot and Karim Fizazi
    Journal for ImmunoTherapy of Cancer 2017 5:31
    Published on: 18 April 2017

    Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)

    CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is t...
    Jeanelle King, Javier de la Cruz and Jose Lutzky
    Journal for ImmunoTherapy of Cancer 2017 5:19
    Published on: 21 March 2017

    Immunotherapy-associated autoimmune hemolytic anemia

    Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-...
    Uqba Khan, Farman Ali, Muhammad Siddique Khurram, Awais Zaka and Tarik Hadid
    Journal for ImmunoTherapy of Cancer 2017 5:15
    Published on: 21 February 2017

    Nivolumab induced myxedema crisis

    Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed...
    Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu and Tarik Hadid
    Journal for ImmunoTherapy of Cancer 2017 5:13
    Published on: 21 February 2017

    PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation

    Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in combi...
    James Godfrey, Michael R. Bishop, Sahr Syed, Elizabeth Hyjek and Justin Kline
    Journal for ImmunoTherapy of Cancer 2017 5:11
    Published on: 21 February 2017

    Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

    Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-...
    Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu and Douglas Johnson
    Journal for ImmunoTherapy of Cancer 2017 5:8
    Published on: 21 February 2017

    Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

    Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by thes...
    Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka and Jose Lutzky
    Journal for ImmunoTherapy of Cancer 2017 5:3
    Published on: 17 January 2017

    Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature

    We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, i...
    Joshua E. Reuss, Paul R. Kunk, Anne M. Stowman, Alejandro A. Gru, Craig L. Slingluff and Elizabeth M. Gaughan
    Journal for ImmunoTherapy of Cancer 2016 4:94
    Published on: 20 December 2016

    Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

    Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the ...
    Jared R. Lowe, Daniel J. Perry, April K. S. Salama, Clayton E. Mathews, Larry G. Moss and Brent A. Hanks
    Journal for ImmunoTherapy of Cancer 2016 4:89
    Published on: 20 December 2016

    Metastatic Merkel cell carcinoma response to nivolumab

    Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) ...
    Frances M. Walocko, Benjamin Y. Scheier, Paul W. Harms, Leslie A. Fecher and Christopher D. Lao
    Journal for ImmunoTherapy of Cancer 2016 4:79
    Published on: 15 November 2016
    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:27

    PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

    Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC). The use...
    Misako Nagasaka, Mark Zaki, Harold Kim, S. Naweed Raza, George Yoo, Ho-sheng Lin and Ammar Sukari
    Journal for ImmunoTherapy of Cancer 2016 4:83
    Published on: 15 November 2016

    Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy– a report of two cases

    Checkpoint inhibitors are a class of agents that employ host’s adaptive immune defenses in fighting cancer. With many new indications and several ongoing clinical trials in a variety of malignancies, the usage...
    Bhaskar C. Kolla and Manish R. Patel
    Journal for ImmunoTherapy of Cancer 2016 4:80
    Published on: 15 November 2016

    Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

    Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors therefore harbor high mutation burdens. In other malignancies, h...
    Gerald S. Falchook, Rom Leidner, Elizabeth Stankevich, Brian Piening, Carlo Bifulco, Israel Lowy and Matthew G. Fury
    Journal for ImmunoTherapy of Cancer 2016 4:70
    Published on: 15 November 2016

    Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

    Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other ch...
    Michael Ong, Andrea Marie Ibrahim, Samuel Bourassa-Blanchette, Christina Canil, Todd Fairhead and Greg Knoll
    Journal for ImmunoTherapy of Cancer 2016 4:64
    Published on: 18 October 2016

    Urothelial carcinoma of donor origin in a kidney transplant patient

    Malignancy after transplantation is an uncommon multifactorial occurrence. Immunosuppression to prevent graft rejection is described as a major risk factor in malignancy development in the post-transplant stat...
    Rosa M. Michel Ortega, Daynna J. Wolff, Cynthia A. Schandl and Harry A. Drabkin
    Journal for ImmunoTherapy of Cancer 2016 4:63
    Published on: 18 October 2016

    Acute visual loss after ipilimumab treatment for metastatic melanoma

    Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related ...
    Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter and Leslie A. Fecher
    Journal for ImmunoTherapy of Cancer 2016 4:66
    Published on: 18 October 2016

    Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade

    Antibodies against programmed death 1 (PD-1) receptor and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have transformed the systemic treatment of melanoma and many other cancers. Understanding the spec...
    Katy K. Tsai, Miguel H. Pampaloni, Charity Hope, Alain P. Algazi, Britt-Marie Ljung, Laura Pincus and Adil I. Daud
    Journal for ImmunoTherapy of Cancer 2016 4:58
    Published on: 20 September 2016

    A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

    Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover’s disease is an uncommon dermatologic condition with unclear patho...
    Marc Uemura, Faisal Faˈak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff and Adi Diab
    Journal for ImmunoTherapy of Cancer 2016 4:55
    Published on: 20 September 2016
    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:7

No hay comentarios:

Publicar un comentario